Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy
Latest Information Update: 09 Nov 2023
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 15 Feb 2023 Status changed from active, no longer recruiting to discontinued.
- 02 Sep 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 02 Sep 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.